Pharma BD Deal Intelligence
Bristol-Myers Squibb struck a deal to buy Seattle-based ZymoGenetics for $885 million, snaring its development partner on a mid-stage hepatitis C program; for…
BMS gains 'the biggest prize' in PEG-IFN lambda inside a global HCV market valued at $4B in 2009 and forecast to $8.5B by 2016 — but the competitive set…
PEG-IFN lambda showed comparable HCV antiviral activity to IFN-alfa with substantially reduced hematologic and flu-like toxicity, but development was overtaken…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
BMS agreed to acquire ZymoGenetics for $9.75/share cash, ~$885M aggregate (~$735M net of cash). Strengthened HCV portfolio (PEG-IFN lambda) and oncology pipeline.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / ZymoGenetics, Inc. (this deal) | 2010 | $885M | 19 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2010 deals · Bristol-Myers Squibb Company deals · Infectious Disease deals